National Health and Medical Research Council (NHMRC, Australia)
オーストラリア
引用
ジャーナル: Nat Commun / 年: 2023 タイトル: Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients. 著者: Romain Rouet / Jake Y Henry / Matt D Johansen / Meghna Sobti / Harikrishnan Balachandran / David B Langley / Gregory J Walker / Helen Lenthall / Jennifer Jackson / Stephanie Ubiparipovic / ...著者: Romain Rouet / Jake Y Henry / Matt D Johansen / Meghna Sobti / Harikrishnan Balachandran / David B Langley / Gregory J Walker / Helen Lenthall / Jennifer Jackson / Stephanie Ubiparipovic / Ohan Mazigi / Peter Schofield / Deborah L Burnett / Simon H J Brown / Marianne Martinello / Bernard Hudson / Nicole Gilroy / Jeffrey J Post / Anthony Kelleher / Hans-Martin Jäck / Christopher C Goodnow / Stuart G Turville / William D Rawlinson / Rowena A Bull / Alastair G Stewart / Philip M Hansbro / Daniel Christ / 要旨: Emerging variants of concern (VOCs) are threatening to limit the effectiveness of SARS-CoV-2 monoclonal antibodies and vaccines currently used in clinical practice; broadly neutralizing antibodies ...Emerging variants of concern (VOCs) are threatening to limit the effectiveness of SARS-CoV-2 monoclonal antibodies and vaccines currently used in clinical practice; broadly neutralizing antibodies and strategies for their identification are therefore urgently required. Here we demonstrate that broadly neutralizing antibodies can be isolated from peripheral blood mononuclear cells of convalescent patients using SARS-CoV-2 receptor binding domains carrying epitope-specific mutations. This is exemplified by two human antibodies, GAR05, binding to epitope class 1, and GAR12, binding to a new epitope class 6 (located between class 3 and 5). Both antibodies broadly neutralize VOCs, exceeding the potency of the clinical monoclonal sotrovimab (S309) by orders of magnitude. They also provide prophylactic and therapeutic in vivo protection of female hACE2 mice against viral challenge. Our results indicate that exposure to SARS-CoV-2 induces antibodies that maintain broad neutralization against emerging VOCs using two unique strategies: either by targeting the divergent class 1 epitope in a manner resistant to VOCs (ACE2 mimicry, as illustrated by GAR05 and mAbs P2C-1F11/S2K14); or alternatively, by targeting rare and highly conserved epitopes, such as the new class 6 epitope identified here (as illustrated by GAR12). Our results provide guidance for next generation monoclonal antibody development and vaccine design.
R: Spike protein S1 H: Heavy chain of Fab arm of antibody 10G4 L: Light chain of Fab arm of antibody 10G4 A: Heavy chain of Fab arm of antibody GAR03 B: Light chain of Fab arm of antibody GAR03 ヘテロ分子
分子量: 24475.314 Da / 分子数: 1 / 由来タイプ: 組換発現 / 詳細: Heavy chain of Fab arm of antibody 10G4 / 由来: (組換発現) Homo sapiens (ヒト) / 細胞株 (発現宿主): ExpiCHO 発現宿主: Cricetulus griseus (モンゴルキヌゲネズミ)
#3: 抗体
LightchainofFabarmofantibody10G4
分子量: 23591.232 Da / 分子数: 1 / 由来タイプ: 組換発現 / 詳細: Light chain of Fab arm of antibody 10G4 / 由来: (組換発現) Homo sapiens (ヒト) / 細胞株 (発現宿主): ExpiCHO 発現宿主: Cricetulus griseus (モンゴルキヌゲネズミ)
#4: 抗体
HeavychainofFabarmofantibodyGAR03
分子量: 24705.656 Da / 分子数: 1 / 由来タイプ: 組換発現 / 詳細: Heavy chain of Fab arm of antibody GAR03 / 由来: (組換発現) Homo sapiens (ヒト) / 細胞株 (発現宿主): ExpiCHO 発現宿主: Cricetulus griseus (モンゴルキヌゲネズミ)
#5: 抗体
LightchainofFabarmofantibodyGAR03
分子量: 22970.273 Da / 分子数: 1 / 由来タイプ: 組換発現 / 詳細: Light chain of Fab arm of antibody GAR03 / 由来: (組換発現) Homo sapiens (ヒト) / 細胞株 (発現宿主): ExpiCHO 発現宿主: Cricetulus griseus (モンゴルキヌゲネズミ)
温度: 293 K / 手法: 蒸気拡散法, ハンギングドロップ法 / pH: 6 詳細: Two uL of protein solution (~5 mg/mL of 1:1:1 complex in 25 mM Tris (pH 8.0), 200 mM NaCl) was combined with an equal volume of well solution (100 mM MMT buffer system (Molecular Dimensions) ...詳細: Two uL of protein solution (~5 mg/mL of 1:1:1 complex in 25 mM Tris (pH 8.0), 200 mM NaCl) was combined with an equal volume of well solution (100 mM MMT buffer system (Molecular Dimensions) (pH 6.0), 19% (w/v) PEG6000.
-
データ収集
回折
平均測定温度: 100 K / Serial crystal experiment: N
放射光源
由来: シンクロトロン / サイト: Australian Synchrotron / ビームライン: MX2 / 波長: 0.9537 Å